Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025
—
ERS
Savara
Poster Title:
Relationship Between Pulmonary Gas Transfer, Respiratory Health-Related Quality of Life (HRQoL), Exercise Capacity, and Surfactant Burden in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: PS-37 / Interstitial Lung Diseases / Respiratory Critical Care / Alveolar Filling Disorders and Autoimmune Lung Diseases
Date/Time of Poster Discussion Session:
Poster Number: PA3027
Location: RAI
Presenter: Francesco Bonella, M.D., Ph.D., Head of the
Poster Title:
Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: PS-37 / Interstitial Lung Diseases / Respiratory Critical Care / Alveolar Filling Disorders and Autoimmune Lung Diseases
Date/Time of Poster Presentation Session:
Poster Number: PA3026
Location: RAI
Presenter: Cormac McCarthy, M.D., Ph.D., FRCPI, Associate Professor of Medicine at the
TrilliumBiO
Poster Title:
Development of a Dried Serum Assay for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Session Title: PS-37 / Interstitial Lung Diseases / Respiratory Critical Care / Alveolar Filling Disorders and Autoimmune Lung Diseases
Date/Time of Poster Presentation Session:
Poster Number PA3025
Location: RAI
Presenter: Eagappanath Thiruppathi, Ph.D., Director of Test and
Savara Industry Evening Mini Symposium
Title: Advances in Autoimmune Pulmonary Alveolar Proteinosis
Date/Time:
Description:
Chair:
Location: E102, RAI Amsterdam
Presenters: Effrosyni D. Manali, M.D., Ph.D.: 2nd
Following the sessions, the posters will be available on the Congresses & Publications page of the Company’s corporate website.
About Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (
View source version on businesswire.com: https://www.businesswire.com/news/home/20250818413518/en/
Media and Investor Relations Contact
ir@savarapharma.com
Source:
